Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,406 across all filing types
Latest filing 2024-05-31 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation
Regulatory Filings Classification · 100% confidence The document is explicitly titled and formatted as a "Press Release" dated May 31, 2024. It discusses an update regarding the FDA's priority review timeline for a supplemental Biologics License Application (sBLA) for Dupixent for COPD, including details about requested efficacy analyses and revised target action dates. This content—an announcement of a regulatory update and clinical trial progress, presented in a concise, public-facing format—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement about a key development (FDA action date extension and clinical data summary) rather than a comprehensive periodic financial report (like 10-K or IR), and it is not merely announcing the publication of a separate report (which would suggest RPA), the most fitting category is Earnings Release (ER), as these press releases often accompany or precede quarterly results announcements, or serve as major operational updates. However, given the focus is purely on regulatory/clinical progress (FDA action date, EMA opinion) and not on quarterly financial figures (revenue, EPS, etc.), it fits better under the general Regulatory Filings (RNS) category, which serves as a fallback for specific operational/regulatory news that doesn't fit the other defined categories like DIV, CAP, or ER (which usually contains key financial metrics). Since the document is a detailed update on a specific regulatory submission and clinical trial data, and it is not a comprehensive financial report, RNS is the most appropriate general classification for significant, non-periodic corporate news. Revisiting the definitions: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document does not contain key financial highlights. It is a press release about a regulatory event. Therefore, RNS (General regulatory announcements and fallback) is the best fit for this specific type of operational/regulatory news update.
2024-05-31 English
Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and discusses an update regarding the FDA's review timeline for Dupixent for COPD, including details about clinical trials (BOREAS, NOTUS), regulatory progress in the EU, and general company/product information. This format—a formal announcement of a specific, time-sensitive corporate or regulatory event (FDA decision delay)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release detailing key operational/regulatory news rather than a full financial statement (10-K, IR) or a transcript (CT), and it is not explicitly announcing the publication of a separate report (RPA), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the focus on a specific regulatory update and the press release format, RNS is a strong candidate, but ER often covers significant operational milestones like this. However, the content is purely operational/regulatory news about a drug application delay, not quarterly financial results highlights. Therefore, it is classified as a general Regulatory Filing (RNS) as it is a formal, non-standard announcement that doesn't fit the other specific categories like DIV, CAP, or MANG.
2024-05-31 French
6-K
Regulatory Filings
2024-05-30 English
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Delisting Announcement Classification · 99% confidence The document is explicitly titled "Press Release" and announces the completion of a major corporate action: the acquisition of Inhibrx, Inc. by Sanofi. This type of announcement, detailing the closing of a transaction, the financial terms, and subsequent corporate restructuring (like the spin-off of Inhibrx Biosciences), is characteristic of a significant corporate event disclosure. While it contains financial details, it is not a formal periodic report (like 10-K or IR). It is a direct announcement of a transaction, which aligns best with the 'M&A Activity' category (TAR) or potentially a general 'Regulatory Filing' (RNS) if TAR wasn't available. Given the explicit focus on the acquisition/merger, TAR is the most precise fit. It is not an Earnings Release (ER), Interim Report (IR), or a proxy statement (DEF 14A/PSI).
2024-05-30 English
Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.
M&A Activity Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces the finalization of an acquisition (Sanofi acquiring Inhibrx, Inc.). It details the financial terms ($1.7 billion cash transaction plus contingent value rights) and the subsequent corporate actions, including the delisting of Inhibrx shares from NASDAQ and the spin-off/trading of Inhibrx Biosciences. This type of announcement, detailing a major corporate transaction like an acquisition, is typically classified as a significant corporate event announcement. While it relates to capital structure changes (SHA) or potentially M&A (TAR), the most fitting general category for a press release detailing a completed transaction and its immediate aftermath, especially when it doesn't fit neatly into the specific financial report categories (10-K, IR, ER), is the general regulatory announcement fallback, RNS, or potentially TAR (Merger/Takeover Activity). Given the focus is on the *completion* of a takeover/acquisition, TAR (Merger Activity) is highly relevant. However, since the definitions provided do not explicitly list a category for 'Acquisition Completion Press Release' and TAR is defined as 'Merger proposals or takeover bids', which usually covers the proposal stage, I will evaluate the other options. Since this is a formal announcement of a major corporate action, and it is not a specific financial report (10-K, IR), nor a management discussion (MDA), nor a capital change announcement (SHA - which usually implies issuing new shares), the most appropriate category among the choices that covers significant, non-standard corporate news is RNS (Regulatory Filings/General Regulatory Announcements), as it is a press release format. Revisiting the definitions: TAR is for M&A activity. An acquisition finalization is the culmination of M&A activity. Therefore, TAR is a stronger fit than the general RNS fallback. Final check: The document describes the closing of an acquisition, which falls under Merger/Takeover Activity (TAR).
2024-05-30 French
6-K
Regulatory Filings
2024-05-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.